Nevertheless, our data suggest that TRPV4 inhibitors may represent an attractive therapy for viral pneumonia as they may both suppress viral load via DDX3X signaling and dampen the associated inflammatory response via the S100A7/RAGE pathway. Here, DDX3X is linked to viral pneumonia.